Peroxisome Proliferator Activated Receptor Delta - Pipeline Review, H1 2018

  • ID: 4451678
  • Report
  • 77 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CymaBay Therapeutics Inc
  • Genfit SA
  • Inventiva
  • Mitobridge Inc
  • Nippon Chemiphar Co Ltd
  • T3D Therapeutics Inc
  • MORE
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H1 2018

Summary

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Peroxisome proliferator-activated receptor delta is a nuclear receptor that in humans is encoded by the PPARD gene. PPAR-delta is a nuclear hormone receptor that governs a variety of biological processes and involved in the development of several chronic diseases, including diabetes, obesity, atherosclerosis, and cancer. The expression of this gene is found to be elevated in colorectal cancer cells. The elevated expression can be repressed by adenomatosis polyposis coli (APC), a tumor suppressor protein involved in the APC/beta-catenin signaling pathway.

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 3, 3 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System, Immunology, Genetic Disorders, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Oncology, Ophthalmology, Dermatology, Respiratory and Undisclosed which include indications Non-Alcoholic Steatohepatitis (NASH), Dyslipidemia, Type 2 Diabetes, Alzheimer's Disease, Duchenne Muscular Dystrophy, Kidney Disease, Liver Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Primary Biliary Cirrhosis, Bone Disorders, Bone Fracture, Colitis, Familial Chylomicronemia (Type I Hyperlipoproteinemia), Homozygous Familial Hypercholesterolemia (HoFH), Hypertriglyceridemia, Idiopathic Pulmonary Fibrosis, Inflammation, Inherited Metabolic Disorders, Liver Fibrosis, Metabolic Syndrome, Mitochondrial Diseases, Neurodegenerative Diseases, Obesity, Osteoarthritis, Osteoporosis, Parkinson's Disease, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Unspecified and Wounds.

The latest report Peroxisome Proliferator Activated Receptor Delta - Pipeline Review, H1 2018, outlays comprehensive information on the Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD)
  • The report reviews Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CymaBay Therapeutics Inc
  • Genfit SA
  • Inventiva
  • Mitobridge Inc
  • Nippon Chemiphar Co Ltd
  • T3D Therapeutics Inc
  • MORE
Introduction

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Overview

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Companies Involved in Therapeutics Development

Chipscreen Biosciences Ltd

Connexios Life Sciences Pvt Ltd

CymaBay Therapeutics Inc

Genfit SA

Inventiva

Mitobridge Inc

Nippon Chemiphar Co Ltd

Senju Pharmaceutical Co Ltd

T3D Therapeutics Inc

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Drug Profiles

CNX-013B2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-038 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elafibranor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fonadelpar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HPP-593 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanifibranor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA-0204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA-0211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTB-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NC-2400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-774 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seladelpar lysine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize PPAR Delta for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PPAR Beta and PPAR Delta for Metabolic Disorders, Inflammatory Diseases and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-3D959 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Dormant Products

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Discontinued Products

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Product Development Milestones

Featured News & Press Releases

Jan 04, 2018: Inventiva Announces Positive DSMB Review in Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor

Nov 06, 2017: Mitobridge Presents Preclinical Data Demonstrating Beneficial Effects of PPARd Modulators in Acute Kidney Injury at American Society of Nephrology Annual Meeting

Oct 31, 2017: CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer

Oct 23, 2017: CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis

Oct 09, 2017: CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting

Sep 20, 2017: GENFIT: Risk of confusion between PPAR alpha/delta Phase 3 drug candidate elafibranor and PPAR a/d/gamma Phase 2 compound lanifibranor

Sep 18, 2017: Inventivas IVA337 Given Generic Name “Lanifibranor”by the World Health Organization (WHO)

Sep 11, 2017: CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis

Aug 15, 2017: CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology

Aug 08, 2017: Mitobridge’s Novel Treatment Approach for Duchenne Muscular Dystrophy Advances into Clinical Development

Jul 27, 2017: Inventiva to Present New Data on IVA337 at the 15th International Workshop on Scleroderma Research in Pittsburgh, USA

Jul 17, 2017: CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis

Jun 20, 2017: Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models

Jun 01, 2017: Positive Outcome from the 1-year Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Therapy Areas, H1

Number of Products under Development by Indications, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products under Investigation by Universities/Institutes, H1

Products under Investigation by Universities/Institutes, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Pipeline by Chipscreen Biosciences Ltd, H1

Pipeline by Connexios Life Sciences Pvt Ltd, H1

Pipeline by CymaBay Therapeutics Inc, H1

Pipeline by Genfit SA, H1

Pipeline by Inventiva, H1

Pipeline by Mitobridge Inc, H1

Pipeline by Nippon Chemiphar Co Ltd, H1

Pipeline by Senju Pharmaceutical Co Ltd, H1

Pipeline by T3D Therapeutics Inc, H1

Dormant Products, H1

Discontinued Products, H1

List of Figures

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Therapy Areas, H1

Number of Products under Development by Top 10 Indications, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Stage and Molecule Type, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Chipscreen Biosciences Ltd
  • Connexios Life Sciences Pvt Ltd
  • CymaBay Therapeutics Inc
  • Genfit SA
  • Inventiva
  • Mitobridge Inc
  • Nippon Chemiphar Co Ltd
  • Senju Pharmaceutical Co Ltd
  • T3D Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll